多発性骨髄腫

Niels W C J van de Donk¹, Charlotte Pawlyn², Kwee L Yong³

¹Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands.

Lancet (London, England)

|January 31, 2021

まとめ

多発性骨髄腫は血液がんの一種で初期症状として発症することが多いのです早期発見とリスクの階層化は効果的な治療戦略と患者の成果の改善の鍵です

科学分野:

血液学
腫瘍学
遺伝学

背景:

多発性骨髄腫は高所得国で2番目に多い血液学的悪性腫瘍です
重要性が不明のモノクローナル・ガンモパシーや炎症性多発性骨髄腫のような前駆性疾患から発症する.
これらの前駆体には既に遺伝的異常があり,ハイパーディプロイド性や免疫グロブリン重鎖の転位も含まれます.

研究の目的:

治療を必要とする症状性多発性骨髄腫とその前駆体状態を区別する.
診断と治療計画におけるリスクの階層化の重要性を強調する.
多発性骨髄腫の治療における現在の研究方向性を概説する.

主な方法:

症状性多発性骨髄腫と前駆体疾患を特定するための診断調査
患者特有の要因 (例えば,パフォーマンス状態) と疾患特有の要因 (例えば,高リスクの細胞遺伝) を含むリスクの階層化.

主要な成果:

治療 (免疫調節薬,プロテアソーム阻害剤,CD38抗体) の進歩にもかかわらず,患者の生存率は限られている.
病気の進行と再発はサブクローンの進化と抵抗性の増加によって引き起こされる.
患者はしばしば高カルセミア,腎不全,貧血,または骨溶解性骨の病変を呈する.

結論:

正確な診断とリスクの分別は多発性骨髄腫とその前駆体疾患の管理に不可欠です
進行中の研究は,最小残留疾患検査,免疫療法,および燃える多発性骨髄腫の早期検知に焦点を当てています.

さらに関連する動画

10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.3K

07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K

関連する概念動画

01:31

Hybridoma Technology

16.5K

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

16.5K

01:27

Disorders of Leukocytes

1.5K

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...

1.5K

02:56

Treatment Resistant Cancers

3.5K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...